Targeting the Epigenetic Machinery to Modulate Anti-tumor Immunity

In person only

Dr. Goswami obtained her medical degree from the Gauhati Medical College in Assam, India, and PhD in Immunology from Baylor College of Medicine in Houston, Texas, USA. She completed her Internal Medicine Residency from the University of Pittsburgh Medical Center (UPMC) in Pittsburgh, PA, and Medical Oncology Fellowship from The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Dr. Goswami has published numerous original research articles and reviews in high-impact journals such as Nature Medicine, Nature Immunology, Science, Nature Reviews Immunology, and Science Translational Medicine which enabled development of novel combination immunotherapy to treat cancer patients. Her clinic is focused on treating patients with renal cell carcinoma and urothelial carcinoma and her laboratory work in the Department of Immunology focuses on understanding the cellular state and plasticity of the tumor-immune ecosystem and its role in determining response to immune checkpoint therapy. Dr. Goswami has designed multiple investigator-initiated clinical trials based on her pre-clinical data and currently leading them as a principal investigator. Recently, Dr. Goswami was elected to be a part of the “Extended Leadership Team” for the B reak Through Cancer (BTC) Glioblastoma (GBM) team, a research alliance between The University of Texas MD Anderson Cancer Center, Dana Farber Cancer Institute, Massachusetts Institute of Technology, Johns Hopkins University, and 2 Memorial Sloan Kettering Cancer Center. As a part of this multi-disciplinary alliance, Dr. Goswami will lead the discovery science work delineating myeloid cell biology to explore therapeutic avenues in GBM. Dr.
Goswami received numerous awards including the Andrew Sabin Award in 2021 for high risk-high impact research for emerging leaders.